Erasca announced robust preliminary efficacy and safety data for its cancer drug ERAS-0015 in lung and pancreatic cancers, with dose escalation and combination trials ahead of schedule. The company also expects early data for its pan-KRAS inhibitor ERAS-4001 in late 2026. Erasca secured $409 million in cash and equivalents as of March 2026, supporting operations into the second half of 2028. Collaborations with Merck and Tango Therapeutics aim to advance combination therapies, highlighting Erasca's potential to transform treatment for RAS-driven cancers.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
